Cynthia X Ma


Affiliation: Washington University School of Medicine
Country: USA


  1. Ma C, Bose R, Gao F, Freedman R, Telli M, Kimmick G, et al. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clin Cancer Res. 2017;23:5687-5695 pubmed publisher
    ..ctDNA sequencing offers a noninvasive strategy to identify patients with HER2mut cancers for clinical trial participation. Clin Cancer Res; 23(19); 5687-95. ©2017 AACR. ..
  2. Ma C, Suman V, Goetz M, Northfelt D, Burkard M, Ademuyiwa F, et al. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. Clin Cancer Res. 2017;23:6823-6832 pubmed publisher
    ..i>Clin Cancer Res; 23(22); 6823-32. ©2017 AACR. ..
  3. Ma C, Gao F, Luo J, Northfelt D, Goetz M, Forero A, et al. NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2017;23:4055-4065 pubmed publisher
    ..i>Clin Cancer Res; 23(15); 4055-65. ©2017 AACR. ..
  4. Liu N, Johnson K, Ma C. Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis. Clin Breast Cancer. 2018;18:e997-e1002 pubmed publisher
    ..43; 95% confidence interval, 1.26-1.61). Similar results were noted in the race and stage subgroup analyses. In recent years, male breast cancer patients have had worse survival outcomes compared with those of female patients. ..
  5. Bagegni N, Thomas S, Liu N, Luo J, Hoog J, Northfelt D, et al. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Res. 2017;19:123 pubmed publisher, NCT01723774. Registered on 6 November 2012. ..